Frederik et al. identified SMOC2 as a potential blood biomarker for enhancing nonalcoholic fatty liver disease (NAFLD) diagnosis through WGCNA and single-cell sequencing, offering a noninvasive alternative to liver biopsy (Larsen et al., 2023). Here, SMOC2 is linked to metabolic dysfunction-associated steatotic liver disease.